Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-21
2000-02-08
Crane, L. Eric
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 86, 514 50, 514 51, 544276, A61K 31505, A01N 4354
Patent
active
060228768
ABSTRACT:
The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.
REFERENCES:
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5684010 (1997-11-01), Schinazi
patent: 5700937 (1997-12-01), Liotta et al.
patent: 5792773 (1998-08-01), Chu et al.
Mar et al., "Some Nucleoside Analogs with Anti-Human Immunodeficiency Virus Activity Inhibit Replication of Epstein-Barr Virus," Antiviral Research, 28, 1-11 (1995). Copy supplied by applicant.
Fields et al. (eds.), Fields' Virology(Third Edition), Lippincott-Raven Publishers, New York, NY, 1996, vol. 2, Chapter 75, pp. 2419-24209.
Berkow et al. (eds.), The Merck Manual of Diagnosis and Therapy(16th Ed.), Merck and Co., Rahway, NJ, 1992, only pp. 74-86, 203-205 & 2281-2285 supplied.
Lee et al., "Dioxolane Cytosine Nucleosides as Anti-Hepatitis B Agents," Bioorganic & Medicinal Chem. Letters, 5(17), 2011-2014 (Sep. 7, 1995).
Wilson et al., "The Synthesis and Anti-HIV Activity of Pyrimidine Dioxolanyl Nucleosides," Bioorganic & Medicinal Chem. Letters, 3(2), 169-174 (Feb. 1993).
Kim et al., "Asymmetric Synthesis of 1,3-Dioxolane-Pyrimidine Nucleosides and Their Anti-HIV Activity," J. Medicinal Chem., 35(11), 1987-1995 (May 29, 1992).
Kim et al. (II), L-.beta.-(2S, 4S-and L-.alpha.-(2S,4R))-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships, J. Medicinal Chem., 36(5), 519-528 (Mar. 5, 1993).
Chu et al. (III), "Asymmetric Synthesis of Enantiomerically Pure (-)-(1'R, 4'R)-Dioxolane-Thymine and Its Anti-HIV Activity," Tetrahedron Letters, 32(31), 3791-3794 (Jul. 29, 1991).
Choi et al., "In Situ Complexation Directs the Stereochemistry of N-Glycosylation in the Synthesis of Oxathiolanyl and Dioxolanyl Nucleosides Analogues," J. American Chem. Soc., 113(24), 9377-9379 (Nov. 20, 1991).
Yao et al., "Inhibition of Epstein-Barr Virus Replication by a Novel L-Nucleoside, 2'-Fluoro-5-methyl-.beta.-L-arabinofuranosyluracil," Biochemical Pharmacology, 51, 941-947 (1996).
Pai et al., "Inhibition of Hepatitis A Virus by a Novel L-Nucleoside, 2'-Fluoro-5-Methyl-.beta.-L-Arabinofuranosyl Uracil," Antimicrobial Agents and Chemotherapy, 40(2), 380-386 (Feb. 1996).
Cheng Yung-Chi
Chu Chung K.
Qu Fucheng
Coleman Henry D.
Crane L. Eric
Sudol R. Neil
Yale University
LandOfFree
L-.beta.-dioxolane uridine analogs and methods for treating and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with L-.beta.-dioxolane uridine analogs and methods for treating and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-.beta.-dioxolane uridine analogs and methods for treating and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1681654